PTC Therapeutics (PTCT) Stock Forecast & Price Target

$45.10 -0.91 (-1.98%)

(As of 09:02 AM ET)

PTC Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 15 Analyst Ratings

Sell
3

Hold
5

Buy
7

Based on 15 Wall Street analysts who have issued ratings for PTC Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 15 analysts, 3 have given a sell rating, 5 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for PTCT.

Consensus Price Target

$44.69
-0.90% Downside

According to the 15 analysts' twelve-month price targets for PTC Therapeutics, the average price target is $44.69. The highest price target for PTCT is $68.00, while the lowest price target for PTCT is $26.00. The average price target represents a forecasted downside of -0.90% from the current price of $45.10.

Get the Latest News and Ratings for PTCT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for PTC Therapeutics and its competitors.

PTCT Analyst Ratings Over Time

Type	Current Forecast 11/28/23 to 11/27/24	1 Month Ago 10/29/23 to 10/28/24	3 Months Ago 8/30/23 to 8/29/24	1 Year Ago 11/28/22 to 11/28/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)	2 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)	7 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	4 Sell rating(s)
Consensus Price Target	$44.69	$40.08	$36.64	$34.85
Forecasted Upside	-0.90% Downside	-1.00% Downside	3.13% Upside	59.19% Upside
Consensus Rating	Hold	Hold	Hold	Reduce

This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

PTCT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PTCT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

PTC Therapeutics Stock vs. The Competition

Type	PTC Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.33	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-3.53% Downside	25,238.47% Upside	6.73% Upside
News Sentiment Rating	Positive News See Recent PTCT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/27/2024	Robert W. Baird 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$48.00 ➝ $52.00	+13.02%
11/26/2024	Wells Fargo & Company 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$56.00 ➝ $68.00	+58.18%
11/19/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$51.00 ➝ $62.00	+56.80%
11/11/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $43.00	-7.80%
10/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$32.00 ➝ $45.00	+15.30%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform
Get the Latest News and Ratings for PTCT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
10/4/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Perform ➝ Sector Perform	$32.00 ➝ $34.00	-4.33%
9/17/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$64.00 ➝ $64.00	+87.08%
9/4/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/26/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Merle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy	$47.00	+33.83%
6/21/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underperform ➝ Underperform	$25.00 ➝ $32.00	-3.88%
5/28/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sell ➝ Sell	$18.00 ➝ $32.00	-14.16%
5/21/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sell ➝ Sell	$18.00 ➝ $26.00	-33.30%
5/20/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$35.00 ➝ $46.00	+15.69%
3/1/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform ➝ Market Perform	$32.00 ➝ $30.00	+6.42%
10/5/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$45.00 ➝ $25.00	+12.61%
9/18/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Schwartz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$44.00 ➝ $30.00	+18.81%
7/20/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$50.00	+24.94%
5/18/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
3/22/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Corwin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/17/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$48.00	-0.21%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:43 AM ET.

PTCT Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for PTC Therapeutics is $44.69, with a high forecast of $68.00 and a low forecast of $26.00.
: 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 3 sell ratings, 5 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PTCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares.
: According to analysts, PTC Therapeutics's stock has a predicted downside of -0.90% based on their 12-month stock forecasts.
: Over the previous 90 days, PTC Therapeutics's stock had 1 upgrade by analysts.
: PTC Therapeutics has been rated by research analysts at Baird R W, Barclays, Cantor Fitzgerald, JPMorgan Chase & Co., Morgan Stanley, Raymond James, Robert W. Baird, Royal Bank of Canada, and Wells Fargo & Company in the past 90 days.
: Analysts like PTC Therapeutics less than other "medical" companies. The consensus rating for PTC Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PTCT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

This page (NASDAQ:PTCT) was last updated on 11/27/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PTC Therapeutics (PTCT) Stock Forecast & Price Target